Last 12 months
Inside the activity.
10 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 9 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 20:42 UTC |
Karnawat Sunil RatilalChief Commercial Officer
|
Tax withholdingCommon Shares | 2,267 | $4.50 | $10,201.50 |
DisclosureSEC source: 0000912282-26-001216 · form4.xml · nonDerivative · entry 1 Karnawat Sunil Ratilal · CIK 0002083506 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,275 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 22:36 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
Tax withholdingCommon Shares | 3,062 | $4.99 | $15,279.38 |
DisclosureSEC source: 0000912282-26-000936 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,851 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:26 UTC |
Evans DaronCFO
|
Tax withholdingCommon Shares | 3,062 | $4.99 | $15,279.38 |
DisclosureSEC source: 0000912282-26-000929 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,400 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:27 UTC |
Elam Nevan CDirector · CEO
|
Tax withholdingCommon Shares | 8,004 | $4.99 | $39,939.96 |
DisclosureSEC source: 0000912282-26-000930 · form4.xml · nonDerivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 605,497 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:59 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 10,000 | $2.85 | $28,500.00 |
DisclosureSEC source: 0000912282-26-000533 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,462 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:18 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
Tax withholdingCommon Shares | 11,439 | $2.99 | $34,202.61 |
DisclosureSEC source: 0000912282-26-000412 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,913 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.07 inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:16 UTC |
Evans DaronCFO
|
Tax withholdingCommon Shares | 11,438 | $2.99 | $34,199.62 |
DisclosureSEC source: 0000912282-26-000411 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,462 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.07, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:07 UTC |
Elam Nevan CDirector · CEO
|
Tax withholdingCommon Shares | 27,618 | $2.99 | $82,577.82 |
DisclosureSEC source: 0000912282-26-000410 · form4.xml · nonDerivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,501 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.07, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:13 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 28,000 | $1.70 | $47,600.00 |
DisclosureSEC source: 0000912282-25-001427 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,352 Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:14 UTC |
Hogenhuis WladimirDirector
|
PurchaseCommon Shares | 5,650 | $1.69 | $9,548.50 |
DisclosureSEC source: 0000912282-25-001429 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,675 Read SEC document |
| December 15, 2025 Filed Dec 15, 2025 19:34 UTC |
Karnawat Sunil RatilalChief Commercial Officer
|
PurchaseCommon Shares | 100 | $1.60 | $160.00 |
DisclosureSEC source: 0000912282-25-001421 · form4.xml · nonDerivative · entry 2 Karnawat Sunil Ratilal · CIK 0002083506 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,542 Read SEC document |
| December 15, 2025 Filed Dec 15, 2025 19:34 UTC |
Karnawat Sunil RatilalChief Commercial Officer
|
PurchaseCommon Shares | 12,000 | $1.62 | $19,438.80 |
DisclosureSEC source: 0000912282-25-001421 · form4.xml · nonDerivative · entry 1 Karnawat Sunil Ratilal · CIK 0002083506 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,442 Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 00:35 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 2,500 | $1.79 | $4,475.00 |
DisclosureSEC source: 0000912282-25-001424 · form4.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #3 Disclosed balance after: 7,000 Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 00:35 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 2,500 | $1.79 | $4,462.50 |
DisclosureSEC source: 0000912282-25-001424 · form4.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #2 Disclosed balance after: 7,000 F2 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.78 to $1.79, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 00:35 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 40,000 | $1.77 | $70,640.00 |
DisclosureSEC source: 0000912282-25-001424 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.81, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 00:35 UTC |
Elam Nevan CDirector · CEO
|
PurchaseCommon Shares | 32,000 | $1.59 | $50,880.00 |
DisclosureSEC source: 0000912282-25-001423 · form4.xml · nonDerivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 641,119 Read SEC document |
| December 09, 2025 Filed Dec 10, 2024 14:11 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 10,549 | $5.04 | $53,166.96 |
DisclosureSEC source: 0000912282-24-000863 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.985 to $5.0559, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:53 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
OtherEmployee Stock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001299 · form4.xml · derivative · entry 3 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Shares · 72,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options vest 1/36th monthly beginning on December 19, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:53 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
GrantCommon Shares | 123,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001299 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,352 F1 · shares: Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 17:44 UTC |
Karnawat Sunil RatilalChief Commercial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001298 · form4.xml · derivative · entry 4 Karnawat Sunil Ratilal · CIK 0002083506 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Shares · 19,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options vest 1/36th monthly beginning on December 19, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 17:44 UTC |
Karnawat Sunil RatilalChief Commercial Officer
|
GrantCommon Shares | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001298 · form4.xml · nonDerivative · entry 1 Karnawat Sunil Ratilal · CIK 0002083506 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,442 F1 · shares: Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:31 UTC |
Evans DaronCFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001292 · form4.xml · derivative · entry 7 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Shares · 63,000 shares Expires 2035-11-19 F3 · derivative.exercise_date: The options vest 1/36th monthly beginning on December 19, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:31 UTC |
Evans DaronCFO
|
GrantCommon Shares | 107,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001292 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,900 F1 · shares: Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:34 UTC |
Elam Nevan CDirector · CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 186,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001294 · form4.xml · derivative · entry 2 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,000 Underlying: Common Shares · 186,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options vest 1/36th monthly beginning on December 19, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:34 UTC |
Elam Nevan CDirector · CEO
|
GrantCommon Shares | 317,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001294 · form4.xml · nonDerivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609,119 F1 · shares: Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:36 UTC |
Labrucherie Gil MDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001279 · form4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:36 UTC |
Labrucherie Gil MDirector
|
GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001279 · form4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,500 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:21 UTC |
KREHER NERISSADirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001290 · form4.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:21 UTC |
KREHER NERISSADirector
|
GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001290 · form4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,576 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:17 UTC |
Hogenhuis WladimirDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001288 · form4.xml · derivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:17 UTC |
Hogenhuis WladimirDirector
|
GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001288 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,025 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:02 UTC |
Harris ErikDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001286 · form4.xml · derivative · entry 2 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:02 UTC |
Harris ErikDirector
|
GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001286 · form4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:49 UTC |
Kim Young-JinDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001283 · form4.xml · derivative · entry 3 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F3 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:49 UTC |
Kim Young-JinDirector
|
GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001283 · form4.xml · nonDerivative · entry 1 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,950 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:41 UTC |
FAUCHET PHILIPPEDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001281 · form4.xml · derivative · entry 2 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026.. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:41 UTC |
FAUCHET PHILIPPEDirector
|
GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001281 · form4.xml · nonDerivative · entry 1 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,500 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| August 18, 2025 Filed Aug 27, 2025 17:17 UTC |
Karnawat Sunil RatilalChief Commercial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000912282-25-000934 · form4.xml · derivative · entry 4 Karnawat Sunil Ratilal · CIK 0002083506 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Shares · 275,000 shares Expires 2035-08-18 F2 · derivative.exercise_date: The options shall vest and become exercisable as follows: One fourth (1/4) of such Options shall vest on the one-year anniversary of the grant date and one thirty-sixth (1/36) of the remaining Options shall vest on the same day of each month thereafter until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Reporting Person's termination of continuous service. Read SEC document |
| August 18, 2025 Filed Aug 27, 2025 17:17 UTC |
Karnawat Sunil RatilalChief Commercial Officer
|
GrantCommon Shares | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000934 · form4.xml · nonDerivative · entry 1 Karnawat Sunil Ratilal · CIK 0002083506 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,442 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/4 on September 1, 2026; 1/4 on September 1, 2027; 1/4 on September 1, 2028; and 1/4 on September 1, 2029. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 13:07 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 2,500 | $4.38 | $10,939.00 |
DisclosureSEC source: 0000912282-25-000718 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,500 F1 · price: The purchaes price reported above is a weight average price. These shares were purchased in multiple transactions at prices ranging from $4.37 to $4.38, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 24, 2025 Filed Jun 24, 2025 16:41 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 5,000 | $4.05 | $20,250.00 |
DisclosureSEC source: 0000912282-25-000706 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,900 Read SEC document |
| June 13, 2025 Filed Jun 23, 2025 13:38 UTC |
Kim Young-JinDirector
|
PurchaseCommon Shares | 1,230,769 | $3.25 | $3,999,999.25 |
DisclosureSEC source: 0000912282-25-000701 · form4.xml · nonDerivative · entry 1 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Handok, Inc. Disclosed balance after: 8,423,386 F1 · ownership.nature: The reporting person disclaims beneficial ownership of the securities held by Handok, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 13, 2025 Filed Jun 23, 2025 13:12 UTC |
KREHER NERISSADirector
|
PurchaseCommon Shares | 3,076 | $3.25 | $9,997.00 |
DisclosureSEC source: 0000912282-25-000699 · form4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,576 Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:19 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000659 · form4.xml · derivative · entry 4 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest as follows: 1/36th monthly beginning on July 10, 2025. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:19 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
GrantCommon Shares | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000659 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,352 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/3 on July 1, 2026; 1/3 on July 1, 2027; and 1/3 on July 1, 2028. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:29 UTC |
Evans DaronCFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000661 · form4.xml · derivative · entry 7 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-06-10 F3 · derivative.exercise_date: The options vest as follows: 1/36th monthly beginning on July 10, 2025. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:29 UTC |
Evans DaronCFO
|
GrantCommon Shares | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000661 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,900 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/3 on July 1, 2026; 1/3 on July 1, 2027; and 1/3 on July 1, 2028. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:07 UTC |
Elam Nevan CDirector · CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000658 · form4.xml · derivative · entry 2 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest as follows: 1/36th monthly beginning on July 10, 2025. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:07 UTC |
Elam Nevan CDirector · CEO
|
GrantCommon Shares | 68,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000658 · form4.xml · nonDerivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,119 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/3 on July 1, 2026; 1/3 on July 1, 2027; and 1/3 on July 1, 2028. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:32 UTC |
Kim Young-JinDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000662 · form4.xml · derivative · entry 3 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2035-06-10 F3 · derivative.exercise_date: The options vest 100% on July 1, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.